
# antibodies -online.com





## anti-APOBEC3F antibody (AA 139-287) (FITC)



Go to Product page

| ( ) | 1/0 | r\ /1 | 014 |   |
|-----|-----|-------|-----|---|
| ( ) | ve  | I V I | -v  | V |
|     |     |       |     |   |

| Quantity:            | 100 μg                                       |
|----------------------|--|
| Target:              | APOBEC3F                                     |
| Binding Specificity: | AA 139-287                                   |
| Reactivity:          | Human  |
| Host:                | Rabbit                                       |
| Clonality:           | Polyclonal                                   |
| Conjugate:           | This APOBEC3F antibody is conjugated to FITC |
| Application:         | Please inquire                               |

### **Product Details**

| Immunogen:        | Recombinant Human DNA dC->dU-editing enzyme APOBEC-3F protein (139-287AA) |  |
|-------------------|---|--|
| Isotype:          | IgG   |  |
| Cross-Reactivity: | Human   |  |
| Purification:     | >95%, Protein G purified  |  |

## Target Details

| Target:           | APOBEC3F  |
|-------------------|---|
| Alternative Name: | APOBEC3F (APOBEC3F Products)  |
| Background:       | Background: DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus |
|                   | replication and retrotransposon mobility via deaminase-dependent and -independent       |

mechanisms. Exhibits antiviral activity against vif-deficient HIV-1. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single- or double-stranded RNA. Exhibits antiviral activity also against hepatitis B virus (HBV), equine infectious anemia virus (EIAV), xenotropic MuLV-related virus (XMRV) and simian foamy virus (SFV) and may inhibit the mobility of LTR and non-LTR retrotransposons. May also play a role in the epigenetic regulation of gene expression through the process of active DNA demethylation.

Aliases: A3F antibody, ABC3F\_HUMAN antibody, APOBEC3F antibody, Apolipoprotein B mRNA editing enzyme, catalytic polypeptide like 3F antibody, Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3F antibody, ARP8 antibody, DNA dC->dU-editing enzyme APOBEC-3F antibody, Induced upon T cell activation antibody, KA6 antibody

UniProt:

Q8IUX4

## **Application Details**

| Restrictions: |  |
|---------------|--|

For Research Use only

#### Handling

| Format:            | Liquid  |  |
|--------------------|---|--|
| Buffer:            | Preservative: 0.03 % Proclin 300<br>Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4                                |  |
| Preservative:      | ProClin   |  |
| Precaution of Use: | This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |  |
| Storage:           | -20 °C,-80 °C   |  |
| Storage Comment:   | Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.   |  |